What governs cake collapse and reconstitution time in lyophilized imipenem-cilastatin sodium for intravenous infusion?

The reference downstream format for parenteral imipenem is a sterile powder produced by aseptic compounding and lyophilization of imipenem monohydrate with cilastatin sodium and sodium bicarbonate. In this format, the principal batch-loss mechanism is collapse or microcollapse of the lyophilized cake during primary drying; collapse is initiated when the product temperature crosses the formulation-specific collapse temperature, which is a function of solute phase behavior rather than a universal value. On production-scale freeze dryers with shelf fluid temperature uniformity of ±0.5 °C, a shelf step increase of 10 °C from freezing to primary drying reduces cycle time but must be justified with batch data from compensated Pirani versus capacitance manometer readings. The formulation addition ratio is fixed on an anhydrous potency basis: imipenem anhydrous 500 mg, cilastatin free acid 500 mg, and sodium bicarbonate 20 mg per vial, corresponding to a mass ratio of 1 : 1 : 0.04. Imipenem monohydrate is weighed at approximately 530 mg for a 500 mg anhydrous label claim, and cilastatin sodium is assay-adjusted to deliver 500 mg of cilastatin free acid. Compounding is performed in water for injection at 2–8 °C under nitrogen blanketing because the β-lactam ring undergoes pH- and temperature-dependent hydrolysis. The solution is prefiltered through a 0.45 μm polyethersulfone membrane and aseptically filtered through a 0.22 μm sterilizing-grade membrane before filling into 20 mL Type I glass vials. A lyophilization cycle in a 24 m² shelf freeze dryer typically includes freezing at -45 °C, primary drying at a shelf temperature of -10 °C with chamber pressure held at 100–150 mTorr, and secondary drying at 30 °C with chamber pressure of 50–80 mTorr. Residual moisture is controlled to ≤ 1.0% water by Karl Fischer titration. The governing compliance references include USP <71> sterility, USP <85> bacterial endotoxins, USP <921> water content, USP <1229.1> lyophilization cycle design, Ph. Eur. 5.1.1, ICH Q3D elemental impurities, 21 CFR Part 211, EU GMP Annex 1, ISO 14644-1 Class 5, and ISO 13408-1:2008 aseptic processing. The finished dosage form is a sterile powder for solution for infusion in a Type I glass vial sealed with a chlorobutyl rubber stopper and aluminum flip-off seal.

Micronized imipenem-cilastatin powder is suspended, not dissolved, for lidocaine-reconstituted intramuscular injection

Intramuscular administration requires a sterile, micronized powder that forms a smooth suspension when reconstituted with lidocaine hydrochloride injection. The formulation addition ratio for the 500 mg presentation is imipenem monohydrate equivalent to 500 mg imipenem and cilastatin sodium equivalent to 500 mg cilastatin; the diluent is 2 mL of lidocaine HCl 1%, providing 20 mg lidocaine and yielding a nominal imipenem concentration of 250 mg/mL upon suspension. Because imipenem is not freely soluble at this concentration, particle size distribution is a release-critical attribute. Sterile micronization is performed with an opposed-jet mill using pharmaceutical-grade nitrogen to achieve a D90 < 20 μm particle size; oversized particles cause needle blockage through a 21-gauge needle and slow suspension equilibration. The micronized imipenem is aseptically blended with sterile cilastatin sodium and sodium bicarbonate in a low-shear double-cone blender under ISO 14644-1 Class 5 conditions. The powder is then filled by auger or vacuum drum filler into Type I glass vials and stoppered under aseptic conditions; terminal sterilization is excluded because of β-lactam thermolability. The relevant compliance framework includes USP <1> injections, USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter in injections, Ph. Eur. 2.9.19 particulate contamination, ICH Q3D elemental impurities, 21 CFR Part 211, and EU GMP Annex 1. The terminal finished product type is a sterile powder for suspension for intramuscular injection in a Type I glass vial.

Stability boundaries of reconstituted imipenem-cilastatin admixtures in elastomeric infusion devices

For ready-to-administer infusion preparation, hospital pharmacies reconstitute the sterile powder in water for injection and transfer the solution into infusion containers. The critical technical constraint is the short aqueous stability window: after reconstitution, the product should be used within 4 hours at 25 °C or within 24 hours at 2–8 °C. The addition ratio in this downstream operation is a dilution ratio rather than a solid-state formula: a 500 mg vial is reconstituted with 10 mL water for injection, then further diluted to 100 mL of 0.9% sodium chloride injection or 5% dextrose injection, producing an imipenem concentration of 5 mg/mL. The process is carried out in a USP <797> compliant ISO Class 5 primary engineering control with closed-system transfer devices to reduce particulate and microbial ingress. Filtration during pharmacy compounding is not required if the reconstituted solution is visually clear and the vial is single-dose; however, some institutions apply a 0.22 μm inline filter during transfer to remove accidental stopper-core particles. Thermal sterilization is contraindicated because aqueous imipenem degrades rapidly at elevated temperature. The governing standards are USP <797>, USP <71>, USP <85>, Ph. Eur. 2.6.1, ICH Q3D, and FDA 21 CFR Part 212 where applicable to outsourcing facilities. The terminal product type is a ready-to-administer IV infusion in Type I glass bottles or polyolefin bags with an administration set compatible with low protein-binding membranes. Published data for elastomeric device stability beyond 4 hours at room temperature is limited.

Control of crystalline habit and residual solvent profile in imipenem monohydrate determines the powder flow and fill weight accuracy on rotary vacuum drum filling lines. The downstream production process for sterile API begins with seeded cooling crystallization from acetone-water mixtures; the antisolvent ratio is typically maintained between 1:8 and 1:12 water-to-acetone by volume, and seed crystal loading is held at 0.1–0.5 wt% relative to dissolved imipenem. Cooling is ramped at 0.1–0.5 °C/min in a jacketed glass-lined crystallizer to minimize uncontrolled nucleation; the resulting crystal size distribution is monitored by laser diffraction under Ph. Eur. 2.9.31 or USP <429>. The wet cake is washed with chilled acetone and vacuum-dried at 35–40 °C to residual moisture ≤ 1.0%; residual acetone is controlled to ICH Q3C Class 3 limits of 5000 ppm. The addition ratio of imipenem to solvent is process-specific and is not a final dosage-form ratio: batch records commonly use 1 kg imipenem monohydrate per 8–12 L of solvent mixture. Terminal sterilization is not applied to the API powder; aseptic processing under EU GMP Annex 1 and ISO 14644-1 Class 5 is required after drying. The terminal product type is a sterile crystalline API powder intended for aseptic dry powder blending, not a finished dosage form.

Imipenem monohydrate exhibits negligible oral absorption; tablet, capsule, and granule formats are therefore constrained to non-systemic local gut sterilisation protocols where systemic exposure is not the therapeutic objective. Published data for this specific configuration is limited. No harmonized pharmacopoeial monograph exists for oral imipenem, so compliance refers only to USP <795> non-sterile compounding, ICH Q3D elemental impurities, and local licensing requirements. A fixed formulation addition ratio for oral tablets or granules has not been established by USP or Ph. Eur.; any ratio must be justified by product-specific development and is not transferable from injectable dosages. The downstream production process for an oral granule would involve roller compaction or direct compression, but these operations do not address nil oral bioavailability. The terminal product type, if produced, would be an unapproved oral tablet, capsule, or granule; no current FDA or EMA licensure pathway is identified for this route of administration.

When relebactam is co-formulated with imipenem and cilastatin in a triple β-lactamase inhibitor powder

Triple fixed-dose combination products add the β-lactamase inhibitor relebactam to the imipenem-cilastatin backbone to extend coverage against carbapenem-resistant Enterobacterales. The formulation addition ratio is imipenem anhydrous 500 mg, cilastatin free acid 500 mg, and relebactam anhydrous 250 mg per vial, a mass ratio of 2 : 2 : 1. The manufacturing process differs from the binary product because relebactam is more soluble and can be sterile-filtered as a separate aqueous stream before aseptic mixing with the imipenem-cilastatin solution. The combined solution is filled into 20 mL Type I glass vials and lyophilized using a cycle comparable to the binary product, with product temperature maintained below the collapse threshold and residual moisture controlled to ≤ 1.0%. The compliance envelope includes USP <71>, USP <85>, USP <1>, Ph. Eur. 2.6.1, ICH Q3D, 21 CFR Part 211, and EU GMP Annex 1. The terminal finished product type is a sterile powder for solution for infusion with a labeled potency of 1.25 g total solids per vial.